| Basics |
Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
|
| IPO Date: |
April 28, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.01B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.45 | 2.60%
|
| Avg Daily Range (30 D): |
$0.48 | 2.23%
|
| Avg Daily Range (90 D): |
$0.34 | 1.96%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.44M |
| Avg Daily Volume (30 D): |
1.43M |
| Avg Daily Volume (90 D): |
.79M |
| Trade Size |
| Avg Trade Size (Sh.): |
100 |
| Avg Trade Size (Sh.) (30 D): |
73 |
| Avg Trade Size (Sh.) (90 D): |
66 |
| Institutional Trades |
| Total Inst.Trades: |
1,667 |
| Avg Inst. Trade: |
$1.75M |
| Avg Inst. Trade (30 D): |
$2.3M |
| Avg Inst. Trade (90 D): |
$1.92M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.35M |
| Avg Closing Trade (30 D): |
$2.06M |
| Avg Closing Trade (90 D): |
$1.47M |
| Avg Closing Volume: |
101.57K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.85
|
$-.26
|
$.03
|
|
Diluted EPS
|
$-.85
|
$-.26
|
$.03
|
|
Revenue
|
$ 134.48M
|
$ 27.61M
|
$ 48.73M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -63.43M
|
$ -19.6M
|
$ 2.32M
|
|
Operating Income / Loss
|
$ -70.61M
|
$ -22.11M
|
$ -.67M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -57.52M
|
$ -33.42M
|
$ 22.05M
|
|
PE Ratio
|
|
|
|
|
|
|
